Mirion Technologies (MIR) Citi's Global Industrial Tech & Mobility Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Citi's Global Industrial Tech & Mobility Conference 2026 summary
18 Feb, 2026Strategic growth and market trends
Nuclear power segment now represents 47% of revenue, with a presence in over 95% of the global operating base, driven by a global shortage in electrical generating capacity.
Small modular reactors (SMRs) and utility-scale new builds are accelerating, with $37 million in SMR orders last year and a strong pipeline for future growth.
Paragon acquisition is fueling 25% expected growth, focusing on replacement parts and instrumentation for the North American fleet.
International expansion includes a sole supplier deal with EDF for 8–14 reactors in France and growing opportunities in Poland, North Africa, the Arab Gulf, and Ukraine.
The installed base is experiencing double-digit organic growth, with operators prioritizing life extension, capacity upgrades, and digital modernization.
Financial performance and guidance
Achieved record orders, backlog, margin expansion, and free cash flow conversion in the past year.
Guidance for 2026 anticipates accelerating organic growth in both core segments, despite crosscurrents in laboratory and radiation therapy businesses.
Backlog remains stable year-over-year, with a $400 million large order pipeline and optimism for continued growth.
Free cash flow conversion improved to 57% of EBITDA, with a target of 60%+ and further productivity improvements expected.
Leverage is at 3.2x EBITDA, with a low cost of debt and a focus on smaller, accretive M&A to further strengthen the portfolio.
Segment updates and operational highlights
Radiation therapy business faced international softness and U.S. capital spending constraints, but fundamentals remain strong with new product launches expected to drive growth in 2026.
Nuclear medicine is positioned for double-digit growth, driven by advances in theranostics and radiopharmaceutical therapies, with strong software and equipment integration.
Medical segment delivered margins above 42% in Q4, with growth expected to continue, though at a more moderate pace.
Margin expansion in nuclear and safety is targeted to reach 30% EBITDA by 2028, leveraging procurement optimization, volume absorption, and AI-driven productivity.
Paragon and Sun Nuclear acquisitions demonstrate a track record of margin improvement through operational discipline and integration.
Latest events from Mirion Technologies
- Q3 2025 saw strong revenue, profit, and cash flow growth, with major nuclear wins and financings.MIR
Q3 202517 Mar 2026 - Record orders and margin expansion in 2025 set the stage for strong 2026 growth.MIR
Q4 202511 Feb 2026 - Guidance raised to 6–8% organic growth and ~30% EBITDA margin by 2028, led by nuclear and medical momentum.MIR
Investor Day 20243 Feb 2026 - Q2 revenue up 5%, adjusted EBITDA up 10.2%, and guidance raised on strong segment growth.MIR
Q2 20242 Feb 2026 - Q1 2024 organic revenue up 5.5% as innovation and ESG drive growth in key markets.MIR
Jefferies Global Healthcare Conference1 Feb 2026 - Q3 revenue up 8.2%, margin expands, and 2024 guidance raised with improved leverage.MIR
Q3 202417 Jan 2026 - Strong growth driven by nuclear tailwinds, recurring revenue, and expanding medical opportunities.MIR
Goldman Sachs Industrials and Materials Conference11 Jan 2026 - Record 2024 results, margin expansion, and strong 2025 outlook driven by nuclear and medical growth.MIR
Q4 202429 Dec 2025 - Q1 2025 delivered revenue, margin, and order growth, with guidance raised despite tariff headwinds.MIR
Q1 202524 Dec 2025